CytomX Therapeutics Inc. (NASDAQ: CTMX) kicked off on January 24, 2023, at the price of $2.72, up 0.73% from the previous trading day. During the day, the shares moved up to $2.78 and dropped to $2.635 before settling in for the closing price of $2.73. Over the past 52 weeks, CTMX has traded in a range of $1.17-$4.73.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 35.80%. While this was happening, its average annual earnings per share was recorded -82.90%. With a float of $65.22 million, this company’s outstanding shares have now reached $65.91 million.
Considering the fact that the conglomerate employs 174 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is +91.61, operating margin of -120.42, and the pretax margin is -120.17.
CytomX Therapeutics Inc. (CTMX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of CytomX Therapeutics Inc. is 0.80%, while institutional ownership is 59.30%. The most recent insider transaction that took place on Jul 20, was worth 10,612. In this transaction EVP, Chief Development Officer of this company sold 7,463 shares at a rate of $1.42, taking the stock ownership to the 62,690 shares. Before that another transaction happened on Jul 20, when Company’s Chief Business Officer sold 4,206 for $1.42, making the entire transaction worth $5,982. This insider now owns 30,725 shares in total.
CytomX Therapeutics Inc. (CTMX) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 6/29/2022, the organization reported -$0.37 earnings per share (EPS), lower than consensus estimate (set at -$0.36) by -$0.01. This company achieved a net margin of -120.17 while generating a return on equity of -120.14. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.24 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -82.90% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.90% during the next five years compared to 4.30% growth over the previous five years of trading.
CytomX Therapeutics Inc. (NASDAQ: CTMX) Trading Performance Indicators
Take a look at CytomX Therapeutics Inc.’s (CTMX) current performance indicators. Last quarter, stock had a quick ratio of 2.00. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.51.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.49, a number that is poised to hit -0.24 in the next quarter and is forecasted to reach -0.97 in one year’s time.
Technical Analysis of CytomX Therapeutics Inc. (CTMX)
Compared to the last year’s volume of 7.17 million, its volume of 2.31 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 44.04%. Additionally, its Average True Range was 0.21.
During the past 100 days, CytomX Therapeutics Inc.’s (CTMX) raw stochastic average was set at 85.41%, which indicates a significant increase from 81.18% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 155.98% in the past 14 days, which was higher than the 93.40% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.85, while its 200-day Moving Average is $1.68. Nevertheless, the first resistance level for the watch stands at $2.81 in the near term. At $2.87, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.95. If the price goes on to break the first support level at $2.66, it is likely to go to the next support level at $2.58. Now, if the price goes above the second support level, the third support stands at $2.52.
CytomX Therapeutics Inc. (NASDAQ: CTMX) Key Stats
The company with the Market Capitalisation of 180.29 million has total of 66,084K Shares Outstanding. Its annual sales at the moment are 69,570 K in contrast with the sum of -83,610 K annual income. Company’s last quarter sales were recorded 16,920 K and last quarter income was -23,300 K.